title: Treatment of osteoporosis: role of bone-forming agents.
authors.affiliation: WHO Collaborating Center for Public Health Aspects of Osteo-Articular Diseases, University of Liège, Liège, Belgium.
authors.forename: J Y
authors.initials: JY
authors.lastname: Reginster
authors.forename: V
authors.initials: V
authors.lastname: Halkin
authors.forename: Y
authors.initials: Y
authors.lastname: Henrotin
authors.forename: C
authors.initials: C
authors.lastname: Gosset
mesh_terms: D045930:Anabolic Agents / Q000627:therapeutic use*; D000818:Animals; D015519:Bone Density / Q000187:drug effects*; D016723:Bone Remodeling / Q000187:drug effects*; D001842:Bone and Bones / Q000187:drug effects / Q000503:physiopathology; D005260:Female; D005459:Fluorides / Q000627:therapeutic use; D013006:Growth Hormone / Q000627:therapeutic use; D006801:Humans; D008297:Male; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000503:physiopathology; D010281:Parathyroid Hormone / Q000627:therapeutic use; D013002:Somatomedins / Q000627:therapeutic use; D013324:Strontium / Q000627:therapeutic use
chemical_list: D045930:Anabolic Agents; D010281:Parathyroid Hormone; D013002:Somatomedins; D013006:Growth Hormone; D005459:Fluorides; D013324:Strontium